Fig. 6: Effect of anti-CD103 and TGF-β neutralizing mAb on tumour growth and PD-1 blockade therapy in B16F10E-KO tumours. | Nature Communications

Fig. 6: Effect of anti-CD103 and TGF-β neutralizing mAb on tumour growth and PD-1 blockade therapy in B16F10E-KO tumours.

From: Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade

Fig. 6

a Neutralizing anti-CD103 mAb inhibits the effect of anti-PD-1. Growth of B16F10E-KO tumours, treated with anti-PD-1 and then receiving anti-CD103 blocking mAb (i.t.) or isotype control. Tumour volumes are given as means ± SEM of six mice/group (*p = 0.043). Data are from two independent experiments out of two. b Cytotoxic activity of CD8+ TIL isolated from B16F10E-KO tumours (n = 3) treated with anti-PD-1 (i.p.) plus isotype control (i.t.) or anti-PD-1 plus anti-CD103 (i.t.). Cytotoxicity against B16F10E-KO tumour cells was determined by a conventional 51Cr release assay at indicated E:T ratios. Data are from one independent experiment out of two (*p = 0.030). c Effects of anti-TGF-β and anti-CD103 neutralizing mAb on tumour growth. Mice were engrafted with B16F10E-KO and then treated with anti-TGF-β, anti-CD103, or isotype control (i.t.). Tumour volumes are given as means ± SEM of six mice/group. Right, tumour weights of B16F10E-KO (n = 6) recovered at day 17 (*p = 0.024). d Left, absolute cell counts of total TIL and right, CD8+ T cells infiltrating B16F10E-KO tumours treated with anti-TGF-β, anti-CD103, or isotype control (n = 6). e Effects of anti-TGF-β neutralizing mAb on PD-1 blockade. Growth of B16F10E-KO tumours, treated with anti-PD-1 and then received anti-TGF-β blocking mAb (i.t.) or isotype control. Tumour volumes are given as means ± SEM of six mice/group (p = 0.196). f Left, absolute counts of total TIL in B16F10E-KO tumours treated with anti-PD-1 plus anti-TGF-β or anti-PD-1 plus isotype control (p = 0.418). Middle panel, absolute counts of CD8+ T cells (p = 0.343) and right, percentages of CD69+CD103+ (*p = 0.020) among CD8+ T cells from B16F10E-KO tumours treated with anti-PD-1 mAb (i.p.) plus anti-TGF-β (i.t.) or anti-PD-1 plus isotype control (n = 6). Each symbol represents an individual tumour; horizontal lines correspond to mean ± SEM (c right, d, f). Data were calculated with unpaired t-test (a−c, e, f) and one-way ANOVA with Tukey’s correction (c right, d.). Source data are provided as a Source Data file.

Back to article page